We are live on ! Find out more
RIGL icon

Rigel Pharmaceuticals
RIGL

107 hedge funds and large institutions have $210M invested in Rigel Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 31 increasing their positions, 42 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

8.92% more ownership

Funds ownership: 0% → 8.92% (+8.9%)

12% less funds holding

Funds holding: 121 → 107 (-14)

23% less call options, than puts

Call options by funds: $202K | Put options by funds: $262K

26% less repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 42

33% less capital invested

Capital invested by funds: $316M → $210M (-$105M)

48% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 27

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
107
Holders Change
-14
Holders Change %
-11.57%
% of All Funds
2.67%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
14
Increased
31
Reduced
42
Closed
27
Calls
$202K
Puts
$262K
Net Calls
-$60K
Net Calls Change
-$2.04M

Top Buyers

1
Wellington Management Group
Wellington Management Group
Massachusetts
+$16.5M
2
BBA
Baker Bros. Advisors
New York
+$5.78M
3
CAM
Cormorant Asset Management
Massachusetts
+$4.91M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$2.12M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$1.87M

Top Sellers

1
BC
Boxer Capital
California
-$4.96M
2
SAM
Senzar Asset Management
New York
-$3.33M
3
Goldman Sachs
Goldman Sachs
New York
-$3.3M
4
PAI
Palo Alto Investors
California
-$2.89M
5
EI
EAM Investors
California
-$2.55M
Name Holding Trade Value Shares
Change 		Change in
Stake
MA
101
MUFG Americas
New York
$2K -$1.92K -67 -50%
PCM
102
Prelude Capital Management
New York
$1K -$11.7K -410 -91%
PFGIA
103
Patriot Financial Group Insurance Agency
Massachusetts
$1K +$859 +30 New
BC
104
Boxer Capital
California
– -$4.96M -135,114 Closed
SAM
105
Senzar Asset Management
New York
– -$3.33M -90,720 Closed
EI
106
EAM Investors
California
– -$2.55M -69,504 Closed
Renaissance Technologies
107
Renaissance Technologies
New York
– -$2.31M -62,980 Closed
LOAMU
108
Lombard Odier Asset Management (USA)
New York
– -$1.73M -47,000 Closed
Balyasny Asset Management
109
Balyasny Asset Management
Illinois
– -$1.38M -37,500 Closed
DCM
110
DAFNA Capital Management
California
– -$1.25M -34,000 Closed
HT
111
HAP Trading
New York
– -$1.13M -30,757 Closed
BIM
112
Bogle Investment Management
Massachusetts
– -$724K -19,744 Closed
GAMA
113
Graticule Asia Macro Advisors
New York
– -$653K -17,800 Closed
SO
114
STRS Ohio
Ohio
– -$644K -17,570 Closed
Acadian Asset Management
115
Acadian Asset Management
Massachusetts
– -$486K -13,248 Closed
SIM
116
Spark Investment Management
New York
– -$310K -8,460 Closed
ECM
117
Endurant Capital Management
California
– -$310K -8,444 Closed
Tudor Investment Corp
118
Tudor Investment Corp
Connecticut
– -$155K -4,224 Closed
CCMH
119
Cornerstone Capital Management Holdings
New York
– -$144K -3,930 Closed
RFS
120
Rockefeller Financial Services
New York
– -$128K -3,495 Closed
Wolverine Trading
121
Wolverine Trading
Illinois
– -$125K -3,490 Closed
HIM
122
Hillsdale Investment Management
Ontario, Canada
– -$93K -2,540 Closed
FMA
123
FNY Managed Accounts
New York
– -$73.4K -2,000 Closed
BCM
124
Bayesian Capital Management
New York
– -$58K -1,593 Closed
BFM
125
Boothbay Fund Management
New York
– -$56K -1,516 Closed
2 3 4
5
6

RIGL Hedge Fund Activity: Q4 2016 in Review

107 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q4 2016, worth a combined $210M — down 33% from $316M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of RIGL and 14 opened new positions — a net loss of 13 holders — while 42 trimmed existing stakes and 31 added.

The largest buyer was Wellington Management Group, adding an estimated $16.5M. The largest seller was Boxer Capital, exiting entirely with an estimated $4.96M sold.

  • 107 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q4 2016, down from 121 in Q3 2016.
  • Funds reported $210M of Rigel Pharmaceuticals stock for Q4 2016, down 33% quarter-over-quarter.
  • 14 funds opened new Rigel Pharmaceuticals positions in Q4 2016 and 27 closed out, a net change of -13 holders.
  • The largest Rigel Pharmaceuticals buyer in Q4 2016 was Wellington Management Group, an estimated $16.5M added.
  • The largest Rigel Pharmaceuticals seller in Q4 2016 was Boxer Capital, an estimated $4.96M sold.

Based on aggregated 13F filings for Q4 2016.